AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.36-1.87 (-1.78%) ▼|ACN177.91+2.11 (+1.20%) ▲|ADBE248.83-6.03 (-2.37%) ▼|AMAT454.01-14.84 (-3.17%) ▼|AMD503.60-17.50 (-3.36%) ▼|AMGN382.47-8.80 (-2.25%) ▼|AMT172.98-2.45 (-1.40%) ▼|AMZN251.89-0.51 (-0.20%) ▼|AVGO360.83-3.55 (-0.97%) ▼|AXP320.71-1.09 (-0.34%) ▼|BA204.80-1.62 (-0.78%) ▼|BAC62.56-0.11 (-0.18%) ▼|BKNG174.33+0.90 (+0.52%) ▲|BLK1,062.40-9.63 (-0.90%) ▼|BMY63.75-0.66 (-1.02%) ▼|BNY162.59+0.08 (+0.05%) ▲|BRK-B507.00+0.28 (+0.06%) ▲|C138.50+0.70 (+0.51%) ▲|CAT805.00-10.56 (-1.29%) ▼|CL87.90-0.13 (-0.15%) ▼|CMCSA25.17+0.58 (+2.36%) ▲|COF207.11-3.75 (-1.78%) ▼|COP137.04+0.51 (+0.37%) ▲|COST902.38-0.22 (-0.02%) ▼|CRM243.00-1.16 (-0.48%) ▼|CSCO107.44-1.99 (-1.82%) ▼|CVS95.29-0.09 (-0.09%) ▼|CVX212.76-1.05 (-0.49%) ▼|DE677.94+0.73 (+0.11%) ▲|DHR200.53-4.32 (-2.11%) ▼|DIS105.82+1.64 (+1.57%) ▲|DUK119.37-1.06 (-0.88%) ▼|EMR148.37-1.97 (-1.31%) ▼|FDX311.80+2.61 (+0.84%) ▲|GD354.25+1.58 (+0.45%) ▲|GE324.15-1.27 (-0.39%) ▼|GEV923.91-27.13 (-2.85%) ▼|GILD144.81-0.84 (-0.58%) ▼|GM86.12+2.36 (+2.82%) ▲|GOOG330.39+2.01 (+0.61%) ▲|GOOGL332.60+1.95 (+0.59%) ▲|GS1,019.77-9.01 (-0.88%) ▼|HD305.69-4.76 (-1.53%) ▼|HON202.18-2.75 (-1.34%) ▼|IBM234.02-5.92 (-2.47%) ▼|INTC100.32-5.92 (-5.57%) ▼|INTU312.77-1.17 (-0.37%) ▼|ISRG360.46+7.22 (+2.04%) ▲|JNJ266.35-0.73 (-0.27%) ▼|JPM353.56-1.15 (-0.32%) ▼|KO87.83+0.28 (+0.32%) ▲|LIN461.62-5.03 (-1.08%) ▼|LLY1,123.00-1.21 (-0.11%) ▼|LMT530.12+5.66 (+1.08%) ▲|LOW196.59-2.01 (-1.01%) ▼|LRCX298.01-17.83 (-5.65%) ▼|MA565.37-2.13 (-0.38%) ▼|MCD253.05-0.43 (-0.17%) ▼|MDLZ62.47+0.05 (+0.08%) ▲|MDT91.62-0.27 (-0.29%) ▼|META644.38-9.31 (-1.42%) ▼|MMM162.86-1.54 (-0.94%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.71-2.82 (-1.91%) ▼|MS212.66-2.69 (-1.25%) ▼|MSFT492.44+0.79 (+0.16%) ▲|MU977.41-50.36 (-4.90%) ▼|NEE82.44-0.21 (-0.25%) ▼|NFLX76.01-0.02 (-0.03%) ▼|NKE36.62-0.73 (-1.95%) ▼|NOW131.17+0.06 (+0.05%) ▲|NVDA218.36-5.31 (-2.37%) ▼|ORCL152.94-8.69 (-5.38%) ▼|PEP136.65-0.04 (-0.03%) ▼|PFE27.65-0.13 (-0.47%) ▼|PG142.97+0.33 (+0.23%) ▲|PLTR165.86-3.67 (-2.16%) ▼|PM189.77+4.06 (+2.19%) ▲|QCOM176.88+0.48 (+0.27%) ▲|RTX198.12+0.57 (+0.29%) ▲|SBUX99.22-0.82 (-0.82%) ▼|SCHW107.33+0.79 (+0.74%) ▲|SO87.75-0.59 (-0.67%) ▼|SPG204.67+0.14 (+0.07%) ▲|T25.55+0.40 (+1.59%) ▲|TMO603.18-2.51 (-0.41%) ▼|TMUS177.16-0.18 (-0.10%) ▼|TSLA363.56-4.25 (-1.16%) ▼|TXN258.82-2.77 (-1.06%) ▼|UBER72.56+1.48 (+2.08%) ▲|UNH388.28-4.78 (-1.22%) ▼|UNP285.78+1.04 (+0.37%) ▲|UPS99.97+0.75 (+0.76%) ▲|USB62.41+0.30 (+0.48%) ▲|V367.21-0.18 (-0.05%) ▼|VZ49.97+0.23 (+0.46%) ▲|WFC89.45-0.22 (-0.25%) ▼|WMT105.73-0.10 (-0.09%) ▼|XOM165.23+1.00 (+0.61%) ▲|AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.36-1.87 (-1.78%) ▼|ACN177.91+2.11 (+1.20%) ▲|ADBE248.83-6.03 (-2.37%) ▼|AMAT454.01-14.84 (-3.17%) ▼|AMD503.60-17.50 (-3.36%) ▼|AMGN382.47-8.80 (-2.25%) ▼|AMT172.98-2.45 (-1.40%) ▼|AMZN251.89-0.51 (-0.20%) ▼|AVGO360.83-3.55 (-0.97%) ▼|AXP320.71-1.09 (-0.34%) ▼|BA204.80-1.62 (-0.78%) ▼|BAC62.56-0.11 (-0.18%) ▼|BKNG174.33+0.90 (+0.52%) ▲|BLK1,062.40-9.63 (-0.90%) ▼|BMY63.75-0.66 (-1.02%) ▼|BNY162.59+0.08 (+0.05%) ▲|BRK-B507.00+0.28 (+0.06%) ▲|C138.50+0.70 (+0.51%) ▲|CAT805.00-10.56 (-1.29%) ▼|CL87.90-0.13 (-0.15%) ▼|CMCSA25.17+0.58 (+2.36%) ▲|COF207.11-3.75 (-1.78%) ▼|COP137.04+0.51 (+0.37%) ▲|COST902.38-0.22 (-0.02%) ▼|CRM243.00-1.16 (-0.48%) ▼|CSCO107.44-1.99 (-1.82%) ▼|CVS95.29-0.09 (-0.09%) ▼|CVX212.76-1.05 (-0.49%) ▼|DE677.94+0.73 (+0.11%) ▲|DHR200.53-4.32 (-2.11%) ▼|DIS105.82+1.64 (+1.57%) ▲|DUK119.37-1.06 (-0.88%) ▼|EMR148.37-1.97 (-1.31%) ▼|FDX311.80+2.61 (+0.84%) ▲|GD354.25+1.58 (+0.45%) ▲|GE324.15-1.27 (-0.39%) ▼|GEV923.91-27.13 (-2.85%) ▼|GILD144.81-0.84 (-0.58%) ▼|GM86.12+2.36 (+2.82%) ▲|GOOG330.39+2.01 (+0.61%) ▲|GOOGL332.60+1.95 (+0.59%) ▲|GS1,019.77-9.01 (-0.88%) ▼|HD305.69-4.76 (-1.53%) ▼|HON202.18-2.75 (-1.34%) ▼|IBM234.02-5.92 (-2.47%) ▼|INTC100.32-5.92 (-5.57%) ▼|INTU312.77-1.17 (-0.37%) ▼|ISRG360.46+7.22 (+2.04%) ▲|JNJ266.35-0.73 (-0.27%) ▼|JPM353.56-1.15 (-0.32%) ▼|KO87.83+0.28 (+0.32%) ▲|LIN461.62-5.03 (-1.08%) ▼|LLY1,123.00-1.21 (-0.11%) ▼|LMT530.12+5.66 (+1.08%) ▲|LOW196.59-2.01 (-1.01%) ▼|LRCX298.01-17.83 (-5.65%) ▼|MA565.37-2.13 (-0.38%) ▼|MCD253.05-0.43 (-0.17%) ▼|MDLZ62.47+0.05 (+0.08%) ▲|MDT91.62-0.27 (-0.29%) ▼|META644.38-9.31 (-1.42%) ▼|MMM162.86-1.54 (-0.94%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.71-2.82 (-1.91%) ▼|MS212.66-2.69 (-1.25%) ▼|MSFT492.44+0.79 (+0.16%) ▲|MU977.41-50.36 (-4.90%) ▼|NEE82.44-0.21 (-0.25%) ▼|NFLX76.01-0.02 (-0.03%) ▼|NKE36.62-0.73 (-1.95%) ▼|NOW131.17+0.06 (+0.05%) ▲|NVDA218.36-5.31 (-2.37%) ▼|ORCL152.94-8.69 (-5.38%) ▼|PEP136.65-0.04 (-0.03%) ▼|PFE27.65-0.13 (-0.47%) ▼|PG142.97+0.33 (+0.23%) ▲|PLTR165.86-3.67 (-2.16%) ▼|PM189.77+4.06 (+2.19%) ▲|QCOM176.88+0.48 (+0.27%) ▲|RTX198.12+0.57 (+0.29%) ▲|SBUX99.22-0.82 (-0.82%) ▼|SCHW107.33+0.79 (+0.74%) ▲|SO87.75-0.59 (-0.67%) ▼|SPG204.67+0.14 (+0.07%) ▲|T25.55+0.40 (+1.59%) ▲|TMO603.18-2.51 (-0.41%) ▼|TMUS177.16-0.18 (-0.10%) ▼|TSLA363.56-4.25 (-1.16%) ▼|TXN258.82-2.77 (-1.06%) ▼|UBER72.56+1.48 (+2.08%) ▲|UNH388.28-4.78 (-1.22%) ▼|UNP285.78+1.04 (+0.37%) ▲|UPS99.97+0.75 (+0.76%) ▲|USB62.41+0.30 (+0.48%) ▲|V367.21-0.18 (-0.05%) ▼|VZ49.97+0.23 (+0.46%) ▲|WFC89.45-0.22 (-0.25%) ▼|WMT105.73-0.10 (-0.09%) ▼|XOM165.23+1.00 (+0.61%) ▲|
30.1 C
New York
Thursday, September 10, 2026

Tag: patient

Sugar Land Medical Weight Loss Expert, Dr. Adelola Ashaye, Launches Metabolic Wellness & Healthy Weight Program at InTouch Primary Care

Dr. Adelola Ashaye has launched Metabolic Wellness & Healthy Weight Program at InTouch Primary Care, offering a personalized, medically guided approach to sustainable weight loss...

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit

MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)
MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics

Omniscient and The Jacobs Institute launch Connectomics Innovation Program to advance stroke recovery and neurologic care with AI-enabled software.

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...

HealthSure 3X Launches Virtual In-Home Medical Services with Improved Access to Quality Care

NEWARK, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- HealthSure 3X, an online health solutions company headquartered in New Jersey, has introduced a fully integrated platform where patients can avail themselves of licensed healthcare professionals at home using virtual in-home medical care. This method caters to growing needs for accessible and flexible healthcare while upholding professional standards and patient safety.

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation...

START and Advarra Unite to Deliver Unmatched Speed, Quality, and Predictability for Early-Phase Oncology Trials

START enhances its global leadership by integrating Advarra's advanced regulatory and technology solutions, creating a seamlessly connected site network to accelerate trials and relieve...

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients

LUNGevity Foundation Joins 2025 LungXperience Tour to Promote Lung Health and Early Detection Across the U.S.

Organization to Participate in 12 National Events as Part of Innovative Health Education Initiative WASHINGTON, July 24, 2025 /PRNewswire/ -- LUNGevity Foundation, the nation's leading...

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex virus (HSV) infections in immunocompromised patients. The company’s lead candidate is a small molecule specifically inhibiting the viral helicase-primase complex, which represents a novel mechanism of action distinct from current HSV therapies.

SMP Digital Signage Player by CAYIN Technology Sets New Standards for Multi-Sector Smart Display Solutions

TAIPEI, July 24, 2025 /PRNewswire/ -- As digital transformation deepens across industries, enterprises increasingly demand visualization and system integration of information. CAYIN Technology announces SMP...

PFPFA Malaysia Officially Launched, Marking Next Chapter in SingWealth Holdings’ Regional Growth

With the launch of PFPFA (Malaysia), SingWealth Holdings deepens its regional presence and strengthens its commitment to delivering trusted, client-centric financial advisory solutions across...

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient